II. Indications

III. Contraindications

  1. Not FDA approved for age <1 year old

IV. Mechanism

  1. Berdazimer Sodium
    1. Topical agent with Antiviral and immunomodulatory activity
    2. Triggers local nitric oxide release
  2. Berdazimer is delivered in a hydrogel polymer
    1. Allows for controlled local release
    2. Hydrogel acts as a proton donor

V. Medications

  1. Available in a carton with 2 tubes (one for Berdazimer Sodium and another for hydrogel)
  2. Expensive (costs $700 per carton in 2025)

VI. Dosing

  1. Apply Topical Gel once daily for up to 12 weeks
  2. Avoid wetting region for 1 hour after application

VII. Adverse Effects

  1. Well tolerated
    1. Discontinuation rates <3%
  2. Allergic Contact Dermatitis
  3. Local irritant dermatitis
    1. Local irritation, erythema or Pruritus at application site

VIII. Safety

  1. Unknown safety in pregnancy
  2. Considered safe in Lactation
    1. However, no available safety data for use in Lactation
    2. Avoid application to the Breast or nipple

IX. Efficacy

  1. NNT 8 (or 20% of patients) for complete clearance at 12 weeks

Images: Related links to external sites (from Bing)

Related Studies